- Abiomed to Present at Upcoming Investor Conferences
- Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes
- Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines
- TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology
- Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year
- Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification
ABIOMED Inc (ABMD:NSQ) closed at 325.98, -15.85% below its 52-week high of 387.40, set on Jan 28, 2021.
254.41Dec 11 2020387.40Jan 28 2021
Markit short selling activity
|Market cap||14.83bn USD|
|EPS (TTM)||3.25 |
Data delayed at least 15 minutes, as of Nov 26 2021 18:00 GMT.